Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT®-DCP study evaluating the efficacy, safety, and tolerability of valbenazine in pediatric and adult participants who ...

Neurocrine Biosciences Phase 3 study of valbenazine for patients with dyskinetic cerebral palsy failed to meet its primary or secondary endpoints. The company said Monday the drug did not meet its ...

Biosciences announced that its Phase 3 KINECT-DCP study evaluating the efficacy, safety, and tolerability of valbenazine in ...

Facing declining mobility from cerebral palsy, one man trained to dance at his friend’s wedding. What started as a goal ...

Where we ask stylish individuals with particular, exacting, or simply exceptional taste to tell us about the things they’re actually buying. Read more here. Board games are a great way to break the ...